Please Wait.....
Report
Japan Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029
Market Report I 2024-02-17 I 70 Pages I Mordor Intelligence
The Japan Oral Anti-Diabetic Drug Market size is estimated at USD 2.42 billion in 2024, and is expected to reach USD 3.02 billion by 2029, growing at a CAGR of 4.60% during the forecast period (2024-2029).
Japanese victims of the COVID-19 pandemic were less numerous than those from other nations, which may be related to genetic variations, features of Japanese culture, and differences in the coagulation system between Japanese and Caucasians. The Osaka Prefectural Government categorized patients as mild, moderate, or severe and assigned them to various alternative accommodations in order to ease hospital overpopulation. Hospitals provide patient care in accordance with national government regulations. They focused on individuals with intermediate conditions or those with acceptable oxygen saturation values despite the presence of symptoms on computed tomography. Type 2 diabetes is linked to a sedentary lifestyle, which fosters the development of innate insulin resistance, in contrast to Type 1 diabetes, which is brought on by immune system dysfunction.
Japan's rising older population, who are more susceptible to disease, as well as an increase in obesity brought on by inactivity and irregular eating patterns, are regarded to be contributing factors to the country's rising diabetes incidence. As a result of being referred to a medical facility based on the findings of the metabolic syndrome examination, which was implemented in 2008 to avoid lifestyle-related disorders, more people have been diagnosed with the disease, which is another factor. With an aging population, diabetes cases are predicted to increase even more in Japan.
Globally, diabetes has become an epidemic; the IDF 2021 estimates that there are 11 million diabetics in Japan. Type 2 diabetes is linked to a sedentary lifestyle, which fosters the development of innate insulin resistance, in contrast to Type 1 diabetes, which is brought on by immune system dysfunction. Hence, Type 1 diabetes can be categorized as insulin-requiring diabetes, whereas Type 2 diabetes can be categorized as insulin-dependent diabetes. As one of the largest geriatric populations in the world, Japan is particularly susceptible to developing type 2 diabetes. With an aging population, diabetes is becoming more prevalent in Japan. Monitoring and controlling blood sugar levels are becoming more common in order to prevent harmful effects, including cardiovascular disease, kidney diseases, and other conditions.
Japan Oral Anti-Diabetic Drug Market Trends
Sodium - glucose cotransport -2 (SGLT-2) inhibitor Segment Occupied the Highest Market Share in the Japan Oral Anti-Diabetic Drugs Market in 2022
In 2020, dapagliflozin and empagliflozin received approval for treatment in patients with persistent symptomatic heart failure in Japan. These medications are sodium-glucose cotransporter 2 (SGLT2) inhibitors. This authorization means that a new significant group of patients is becoming eligible for therapy with an SGLT2 inhibitor following the rapid growth of prescriptions for SGLT2 inhibitors for patients with type 2 diabetes mellitus who also have a very high cardiovascular risk. Type 2 diabetes is related to adopting a sedentary lifestyle, which results in the development of innate resistance to insulin, in contrast to Type 1 diabetes, which is brought on by an immune system failure. As a result, Type 1 diabetes is known as insulin-required diabetes, and Type 2 diabetes is known as insulin-dependent diabetes. One of the greatest elderly populations in the world is found in Japan, where type 2 diabetes is more likely to develop. As Japan's population continues to age, diabetes is becoming more common. Blood glucose levels are increasingly being monitored and managed in order to prevent adverse effects like cardiovascular disorders. Throughout, the incidence of type-2 diabetes is increasing, which boosts demand for SGLT2 drugs. Prices are comparatively high in this location. Jardiance holds a 50% market share in the SGLT2 market in the US. Only one diabetic drug, Jardiance's active pharmacological component, lowers the risk of cardiovascular death in people with Type-2 diabetes.
Owing to the aforementioned factors, the market is expected to grow during the forecast period.
Increasing Diabetes Population in Japan is driving the market.
In January 2021, an article was published, 'Current trends in diabetes mellitus database research in Japan,' funded by AstraZeneca and Ono Pharmaceutical Co., Ltd., stated that East Asians tend to develop type 2 diabetes mellitus with a lower mean body mass index (BMI) compared with that in Caucasians, concomitantly having a greater amount of body fat with a tendency of visceral adiposity at any BMI. In Japanese patients, diabetes develops at a younger age and is characterized by early ?-cell dysfunction with the coexistence of insulin resistance due to increased visceral adiposity.
According to an article published in 2022, 'Dietary Patterns and New-Onset Type 2 Diabetes Mellitus in Evacuees after the Great East Japan Earthquake: A 7-Year Longitudinal Analysis in the Fukushima Health Management Survey', there is evidence of associations between dietary behaviors or diet quality indices, food groups, single foods, and beverages, specific macronutrients and micronutrients, and the incidence of type 2 diabetes mellitus in Japan. Dietary patterns are considered to play a role in the onset or prevention of type 2 diabetes mellitus. The westernized diet makes Japanese people more prone to developing type 2 diabetes mellitus. While traditional Japanese food is characterized by low fat and calorie content, a shift in people's preference for processed food with higher animal fat and calories is thought to have increased abdominal adiposity.
It is therefore anticipated to drive the category expansion during the forecast period because of the aforementioned factors.
Japan Oral Anti-Diabetic Drug Industry Overview
The Japan oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028)
5.1.1 Biguanides
5.1.1.1 Metformin
5.1.2 Alpha-Glucosidase Inhibitors
5.1.2.1 Alpha-Glucosidase Inhibitors
5.1.3 Dopamine D2 Receptor Agonist
5.1.3.1 Bromocriptin
5.1.4 SGLT-2 inhibitors
5.1.4.1 Invokana (Canagliflozin)
5.1.4.2 Jardiance (Empagliflozin)
5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.4.4 Suglat (Ipragliflozin)
5.1.5 DPP-4 inhibitors
5.1.5.1 Onglyza (Saxagliptin)
5.1.5.2 Tradjenta (Linagliptin)
5.1.5.3 Vipidia/Nesina(Alogliptin)
5.1.5.4 Galvus (Vildagliptin)
5.1.6 Sulfonylureas
5.1.6.1 Sulfonylureas
5.1.7 Meglitinides
5.1.7.1 Meglitinides
6 MARKET INDICATORS
6.1 Type-1 Diabetic Population (2017 - 2028)
6.2 Type-2 Diabetic Population (2017 - 2028)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Takeda
7.1.2 Novo Nordisk
7.1.3 Pfizer
7.1.4 Eli Lilly
7.1.5 Janssen Pharmaceuticals
7.1.6 Astellas
7.1.7 Boehringer Ingelheim
7.1.8 Merck And Co.
7.1.9 AstraZeneca
7.1.10 Bristol Myers Squibb
7.1.11 Novartis
7.1.12 Sanofi
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security